NeurogesX Price / Sales Ratio: 1.58
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
None selected
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
NGSX Price / Sales Ratio Rankings
| Overall | 42nd percentile | 2500 of 4365 |
| Sector | 65th percentile | 158 of 457 in Healthcare |
| Industry | 84th percentile | 6 of 38 in Drug Manufacturers - Other |
About Price to Sales Ratio
The price to sales ratio (PS ratio) is calculated by dividing stock price by the revenue per share. It is most useful for comparing companies within a sector or industry because "normal" values for this ratio vary from industry to industry. In general, low price to sales ratios are more appealing because they suggest that a company is undervalued.
An example illustrating why PS ratios should not be compared across industries: On June 21, 2010, Starbucks had a PS ratio of 1.12 while Yahoo! had a PS ratio of 2.56. In other words, Yahoo! shareholders were paying $2.56 for $1 of sales while Starbucks shareholders would only pay $1.12 for $1 of sales. However, at that same moment, the two companies' price to earnings ratios were virtually identical (Starbucks: 28.09 and Yahoo!: 27.78). Hence, shareholders were paying nearly the same amount for $1.00 in earnings. The PS ratios, though, are less comparable since Yahoo!'s profit margins are much higher than that of Starbucks.
Learn More
You may also be interested in these NGSX related companies
NGSX News
Pre-Open Movers 2/10: (CIE) (ALU) (LNKD) Higher; (AMRS) (GDI) (LF) Lower (more...)
Feb 10, 9:31AM Street Insider
Feb 10, 9:31AM Street Insider
NeurogesX (NGSX) Confirms FDA Panel Did Not Recommend Approval of Qutenza
Feb 09, 5:47PM Street Insider
Feb 09, 5:47PM Street Insider
FDA Panel Votes 12-0 Against Effectiveness of NeurogesX's (NGSX) Qutenza
Feb 09, 2:35PM Street Insider
Feb 09, 2:35PM Street Insider
$NGSX Qutenza Patch Doesn't Treat Pain in HIV Patients; Panels Votes 12-0 Against the Drug
about 3 days ago by Benzinga
about 3 days ago by Benzinga
NeurogesX' Stock Trading Halted Today Ahead of Drug Advisory Committee Meeting
Feb 09, 7:04AM Benzinga
Feb 09, 7:04AM Benzinga
FDA Reviewers Say $NGSX Qutenza Shows Statistically Significant Pain Reduction in HIV Patients -Reuters
about 5 days ago by Benzinga
about 5 days ago by Benzinga
NeurogesX, Inc. (NGSX) Names Ronald Martell President and Chief Executive Officer
Jan 03, 10:05AM Street Insider
Jan 03, 10:05AM Street Insider
NeurogesX (NGSX) Reports FDA Committee will Review sNDA for Qutenza 8% Patch
Dec 15, 2:42PM Street Insider
Dec 15, 2:42PM Street Insider
NeurogesX Confirms FDA Advisory Committee to Review sNDA for Qutenza 8% Patch
Dec 15, 2:41PM Benzinga
Dec 15, 2:41PM Benzinga
out 1/2 5k $ngsx $2.21 from $1.8 not much volume,,,stop 2.17-15 rest 1/2
about 199 days ago by treenhome
about 199 days ago by treenhome
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| NGSX | 0.58 | -0.22 | -27.50% | 17.22M |
| AMAT | 12.95 | -0.16 | -1.22% | 17.06B |
| APA | 105.13 | -1.55 | -1.45% | 40.36B |
| CSCO | 19.89 | -0.10 | -0.53% | 106.74B |
| ELNK | 7.94 | -0.09 | -1.12% | 855.77M |
| CREE | 28.35 | -1.47 | -4.93% | 3.29B |
| LOGI | 8.52 | -0.09 | -1.05% | 1.54B |
| VZ | 37.69 | -0.23 | -0.61% | 106.70B |
| RY | 53.46 | -0.54 | -1.00% | 76.89B |
| CTIC | 1.08 | -0.02 | -1.82% | 208.31M |
